© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
March 14, 2012
March 01, 2012
February 28, 2012
Pharmacists can prepare for change by taking careful stock of the services they want to provide now and in the future.
February 27, 2012
February 22, 2012
February 20, 2012
Disease State Management
Technology Product News
The growth of this field is dependent upon connecting stakeholders in a productive way.
Rx Product News Profile
The FDA approved Lazanda (fentanyl) nasal spray for the management of breakthrough pain in opioid-tolerant cancer patients 18 years or older.
Rx Product News
Some important safety measures, such as asking open-ended questions, are neither complicated nor costly.
As more patients begin medication regimens that include rivaroxaban, pharmacists should be aware of its known interactions.
When patients ask about this troublesome ophthalmic condition, pharmacists can recommend helpful management techniques.
Elizabeth O'Hara puts patients at ease with her compassionate, and sometimes humorous, approach.
OTC Product News
Topical preparations can relieve the symptoms of both allergic and irritant contact dermatitis.
When recommending OTC products for these common ailments, a careful patient assessment is an important first step.
OTC Case Studies
Is a pharmacy liable when an employee releases private health information about a patient?
February 15, 2012
A new formulation of hydrocodone currently in development has lawmakers and drug abuse prevention professionals concerned.
Generic Times News
With an all-oral combination therapy and a hepatitis C vaccine on the horizon, pharmacists and patients will soon have new resources against this prevalent infection.
Generic Times Product NEWS
Patients taking antiretroviral therapy can maximize their therapy when pharmacists educate them about their medication regimens.
Generic Times Feature
As blockbuster drugs begin losing patent protection, pharmaceutical companies and pharmacists will address key marketplace changes.
Can You Read These Rxs?